Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes
Launched by VIRGINIA COMMONWEALTH UNIVERSITY · Nov 28, 2022
Trial Information
Current as of January 17, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special program designed to help young people with type 1 diabetes (T1D) transition from pediatric (children's) to adult medical care. The program aims to prepare adolescents and young adults, aged 16 to 22, and their caregivers for this important change. Participants will include those who have been diagnosed with T1D for at least a year and are patients at the Children's Hospital of Richmond. To take part, young people must be fluent in English and have a caregiver who is willing to join the study.
During the trial, participants can expect to engage in activities that will help them learn how to manage their diabetes more independently as they prepare for adult healthcare. The study will gather information that can help improve the way young people with T1D are supported during this transition. It's important to note that certain individuals, such as those with significant mental health issues or other serious health conditions, may not be eligible to participate. This research is a great opportunity for eligible young people and their caregivers to contribute to better care practices for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- AYA:
- • 1. Type 1 Diabetes diagnosis for at least 1 year (as documented in medical record)
- • 2. 16-22 years old
- • 3. English speaking
- • 4. Children's Hospital of Richmond patient (Division of Pediatric Endocrinology)
- • 5. must have a caregiver willing to participate
- Caregiver:
- • 1. Age greater than 18 years
- • 2. Provides care to AYA and willing to participate
- Exclusion Criteria:
- AYA:
- • 1. Non-English speaking
- • 2. Significant psychiatric, cognitive, medical or developmental conditions that would impair their ability to complete assessments and/or engage in diabetes self-care behaviors (e.g., malignancies, psychosis, intellectual disability
- • 3. Hospitalization for depression, suicidal ideation or other psychiatric disorder within the past 12 months. Life time history of psychotic disorder
- • 4. Medically-induced diabetes or diagnosis of diabetes other than type 1 diabetes.
- • 5. Currently pregnant, pregnant within the past 6 months, currently breastfeeding or planning to become pregnant within the next 12 months.
- • 6. Another member of the household (other than the participating parent) is a participant or staff member on this study.
- • 7. Participation in another research study that may interfere with this study.
- • 8. Previous participation in the SHIFT pilot study
- Caregiver:
- • 1. Non-English speaking
- • 2. Significant psychiatric, cognitive, developmental conditions that would impair their ability to complete assessments and/or engage in supporting the AYA with diabetes self-care behaviors (e.g., psychosis, intellectual disability)
- • 3. Another member of the home (not AYA) is a participant/staff member on current study
- • 4. Participation in another research study that may interfere with current study
- • 5. Previous participation in SHIFT pilot study
Trial Officials
Laura Caccavale
Principal Investigator
Virginia Commonwealth University
About Virginia Commonwealth University
Virginia Commonwealth University (VCU) is a prominent academic institution and research leader located in Richmond, Virginia. Renowned for its commitment to advancing healthcare through innovative research and education, VCU plays a pivotal role in clinical trials aimed at improving patient outcomes and understanding complex health issues. The university boasts a collaborative environment, leveraging its diverse faculty expertise and state-of-the-art facilities to conduct rigorous clinical research across various medical disciplines. VCU's dedication to ethical research practices and community engagement ensures that its clinical trials are designed to address critical health challenges while prioritizing participant safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Richmond, Virginia, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials